To compare the effects of D5LR and invert sugar administered intrapartum on neonatal blood glucose concentrations.
Recently, our group reported on the relative effects of antepartum and intrapartum maternal blood glucose levels on the incidence of neonatal hypoglycemia. 1 We established that intrapartum blood glucose control was a key factor in minimizing the incidence and severity of neonatal hypoglycemia in infants of insulin-requiring diabetic patients.
Ten percent invert sugar (mixture of 5% fructose and 5% glucose) was used as the vehicle to provide maternal calories, with insulin given intravenously (i.v.) by continuous infusion to maintain a maternal blood glucose concentration of Ͻ100 mg/dl. 1 Other data 2,3 support the use of fructose solutions to minimize neonatal hypoglycemia.
Invert sugar is expensive, and in our institution, indications for its use have been limited to diabetic women during the intrapartum period. Therefore, we elected to conduct a randomized controlled trial to compare the effects of invert sugar and lactated Ringer's solution with 5% dextrose (D5LR) on neonatal blood glucose concentration and incidence of neonatal hypoglycemia.
MATERIALS AND METHODS
A total of 32 insulin-requiring diabetic patients with single term pregnancies were recruited for participation in the study. Informed consent was obtained. Criteria for induction included Ն38 weeks' gestational age, documented fetal lung maturity, or maternal/fetal indications. The patients were admitted the night before the scheduled induction or elective cesarean section and were then randomized to receive either an i.v. solution of 10% invert sugar or D5LR at a rate of 125 ml/hour. Randomization was done with the use of a computergenerated random-number table. The solution was blinded to both the obstetrician and the pediatrician evaluating the neonate. In addition to the i.v. solution, regular insulin was administered i.v. with an infusion pump at a rate of 1 to 4 U/hour to maintain the plasma glucose concentration between 60 and 90 mg/dl. Additional boluses of 2 to 5 U of regular insulin were given if the plasma glucose concentration was Ͼ90 mg/dl. Once the desired control was achieved for at least 8 hours, either induction with oxytocin or misoprostol was begun, or cesarean section was performed, if indicated. To show a change in mean neonatal blood glucose of 20 meq/dl, we calculated that 13 patients would be needed in each group for a power of 80% with an end result of less than 0.05.
All neonates were monitored for hypoglycemia according to our protocol. 1 Hypoglycemia was defined as a plasma glucose concentration of Ͻ30 mg/dl in the first 24 hours of life and Ͻ40 mg/dl thereafter. 4, 5 We compared the admission, 30-minute, 1-hour, and average neonatal blood glucose levels as well as incidence of admission to the neonatal intensive care unit, neonatal hypoglycemia, and total length of neonatal stay.
Analysis of the data on mean neonatal blood glucose and mean neonatal length of stay was performed using a Student's t-test for Original Article
continuous variables. Categorical data such as the incidence of neonatal intensive care unit admission and neonatal hypoglycemia were compared using Fisher's exact test. Ordinal data such as maternal parity were compared using the Wilcoxon exact test.
RESULTS
The results are summarized in Table 1 . A total of 32 patients were randomized to the study; however, six patients were excluded. The groups had equal numbers of type I and type II diabetics. Complete newborn data were available on all 26 patients who completed the protocol. The two groups did not differ with regard to maternal age, parity, gestational age, or prenatal glycohemoglobin values. They also did not differ in newborn weight, average admission glucose, average glucose, length of stay, incidence of neonatal intensive care unit admissions, incidence of neonatal hypoglycemia, or average maternal blood glucose concentration before delivery.
DISCUSSION
Pribylova et al. 2 and McCann et al. 3 have reported higher neonatal blood glucose levels when antenatal fructose was given for maternal glycemic control compared with glucose. Pribylova et al. compared 45 healthy newborns born to mothers that received fructose (15), mothers that received glucose (10), and controls (20). They reported that in those infants exposed to prenatal fructose infusions, the initial concentration of blood glucose was significantly higher than in the control group. After prenatal glucose infusions, the average value of neonatal blood sugars in the umbilical vein peaked higher, but ended up lower those for both the fructose-treated group and the control group. One reason for our different results maybe that neonates in our nursery are fed almost immediately on arrival to the nursery, and frequent breast-or bottle-feeding is encouraged. Only 5 of 26 (19%) of these infants required i.v. therapy.
Our study only had sufficient power to show that we did not demonstrate a difference of 20 mg/dl in the neonatal blood glucose level, which is not a very ambitious goal. However, to show a significant difference in the incidence of hypoglycemia, 120 patients would be required in each group. Based on our results, we do not think it is worthwhile to continue this study.
Invert sugar is considerably more expensive than D5LR, $6.00 per liter compared with $0.74. By not using invert sugar, approximately $350 per year on i.v. fluids alone can be saved. Based on the absence of differences in the results between the two solutions and based on significant cost savings, we can conclude that D5LR is the preferable choice of solution for intrapartum management of insulin-requiring diabetics.
